Mehmet Sayarlioglu

Mehmet Sayarlioglu

Auto-generated profile, based on publicly available information

Mehmet Sayarlioglu

Department of Internal Medicine, Division of Rheumatology, Sutcu Imam University Medical Faculty, Kahramanmaras, Turkey

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2004 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
MSM. Sayarlioglu
M. Sayarlioglu
ACA. Cefle
A. Cefle
MIM. Inanc
M. Inanc
SKS. Kamali
S. Kamali
EDE. Dalkilic
E. Dalkilic
MKM. Konice
M. Konice
It has been generally accepted that the clinical onset of familial Mediterranean fever (FMF) begins before 20 years of age in most patients. In this study, we aimed to investigate the demographic and clinical characteristics of our FMF patients with an age of onset > or =20. Records of 401 patients (female/male: 204/197) that followed up between 1990 and 1999 were reviewed according to a pre-defined protocol. All patients fulfilled the diagnostic criteria of Livneh et al. The demographic and clinical features of adult-onset FMF patients were compared to those of patients with a disease onset before 20 years of age. There were 57 patients (14%) who experienced symptoms of FMF at > or =20 years of age; 34 of them (8.5%) reported their first attack between 20 and 29 years of age; 18 of them (4.5%) between 30 and 39 years of age and five patients (1.25%) had their first attack after 40 years of age. Arthritis (42 vs. 65%, p = 0.001) and erysipelas-like erythema (7 vs. 17%, p = 0.047) were significantly less frequent in patients with adult-onset FMF compared to patients with disease onset before 20 years of age. Arthritis and erysipelas-like erythema were less frequent in adult-onset patients compared to those with an earlier disease onset. Adult-onset FMF may be a form of disease with distinct clinical, demographic and molecular characteristics. Prospective clinical studies and investigation of genotypic features are needed to identify the characteristics of this phenotypic variant.

1 April 2004 in Lupus
Verified
Journal Article
Closed access
MSM Sayarlioglu
M Sayarlioglu
MIM Inanc
M Inanc
SKS Kamali
S Kamali
ACA Cefle
A Cefle
OKO Karaman
O Karaman
MKM Konice
M Konice
The objectivewas to investigatethe frequencyand characteristicsof tuberculosis(TB) in patients with systemic lupus erythematosus (SLE). We reviewed the charts of 556 patients with SLE who were followed up between 1978 and 2001 in our lupus clinic. Patientswho developedTB after the diagnosis of SLE were identified (SLE/TB). Ninety-six consecutive patients with SLE who did not develop TB during the follow-up were evaluated as a control group (SLE/TB-). Clinical, laboratory and management characteristics of these two groups of patients were recorded according to a predefined protocol, and compared. Of the 556 patients evaluated, 20 patients (3.6%) with TB were identified. Nine of the 20 patients (45%) had extrapulmonary TB (vertebral involvement in three patients, meningeal in two, and joint and soft tissue in four). Arthritis and renal involvement were significantly high in the SLE/TB group (P 0.045, P 0.009, respectively). The mean daily dose of prednisolonebefore the diagnosis of TB and the cumulative dose of prednisolonewere significantly higher in the SLE/TB group compared to the SLE/TB- group (27 + 22 g versus 16 + 16 g, 24 + 45 mg versus 11 + 8.5 mg, respectively). In conclusion, we found an increased frequency of TB infection and a high prevalence of extrapulmonary TB in a large cohort of SLE patients. The mean daily dose of prednisolonebefore the diagnosisof TB and the cumulativedose of prednisolone, which possibly related to disease severity, were important determinants for the increased risk of TB in these patients with SLE.


1 May 2004 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
MSMehmet Sayarlioglu
Mehmet Sayarlioglu
MKMehmet Cetin Kotan
Mehmet Cetin Kotan
NTNazan Topcu
Nazan Topcu
IBIrfan Bayram
Irfan Bayram
HAHasan Arslanturk
Hasan Arslanturk
AGAhmet Gul
Ahmet Gul
OBJECTIVE: To report the beneficial effects of thalidomide on recurrent perforating intestinal ulcers in a patient with Behçet's disease (BD). CASE SUMMARY: A 24-year-old Turkish woman with BD was admitted to our hospital because of severe abdominal pain and vomiting. She had been receiving colchicine 1.5 mg/day and azathioprine 150 mg/day for treatment of BD for 2 years. During emergency laparatomy, 2 perforating ulcers were detected in the anterior cecum, which were treated with debridement and primary repair. She experienced 2 more episodes of intestinal perforations during the second and fifth weeks despite intense immunosuppressive treatment with methylprednisolone and cyclophosphamide. New intestinal perforations were found in the posterolateral cecum and transverse colon during the second operation and in the terminal ileum during the third one. Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks. The woman experienced no other intestinal perforation during the follow-up period of 4 months. DISCUSSION: The mode of action of thalidomide in BD is still unclear. In BD, various cytokines have been shown to be abnormally expressed and neutrophils are overactive. This is a possible mechanism of action with thalidomide reducing both tumor necrosis factor and the neutrophil migration. CONCLUSIONS: Thalidomide may be an effective alternative treatment for BD patients with recurrent and perforating intestinal ulcers despite intense immunosuppressive therapy.

6 October 2004 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
MSM. Sayarlioglu
M. Sayarlioglu
ACA. Cefle
A. Cefle
SKS. Kamali
S. Kamali
AGA. Gul
A. Gul
MIM. Inanc
M. Inanc
MKM. Konice
M. Konice
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder mainly affecting young women. In this study, we aimed at investigating the clinical, laboratory and management characteristics of our SLE patients with an age of onset > or =50. Twenty patients with late onset SLE (> or =50 years) were identified from the records, on the basis of their first SLE-related symptoms (Group I). A hundred consecutive SLE patients with initial symptoms before the age of 50 were also selected as controls (Group II). Clinical, laboratory and management characteristics of the patients were recorded according to pre-defined protocol and compared by chi(2), Student's t-test and Fisher's exact test. Comparison of the demographic findings between the Group I (F/M: 18/2) and the Group II (F/M: 90/10) were as follows: the mean age of disease onset was 53.9 +/- 4.5 years vs. 26.3 +/- 9.2 years, mean time of follow-up was 44.2 +/- 40.5 months vs. 50.1 +/- 47.4 months, mean damage index was 0.6 +/- 0.6 vs. 0.58 +/- 1.4. There was no significant difference between the two groups with regard to clinical, laboratory parameters, damage index and immunosuppressive treatment characteristics. SLE-related manifestations were similar in two groups except fever (10% in the Group I vs. 41% in the Group II; p = 0.01). The only two patients with pulmonary fibrosis were found in the Group I (p = 0.027). The clinical and laboratory characteristics and the disease outcome in SLE patients with an age of onset > or =50 years did not show significant differences from the control SLE patients with a younger age of onset.

21 December 2011 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
BKBunyamin Kisacik
Bunyamin Kisacik
SKSuheyla Uzun Kaya
Suheyla Uzun Kaya
YPYavuz Pehlivan
Yavuz Pehlivan
TTTurker Tasliyurt
Turker Tasliyurt
MSMehmet Sayarlioglu
Mehmet Sayarlioglu
AOAhmet Mesut Onat
Ahmet Mesut Onat